Jin-fang Zhang

Prof. Jin-fang Zhang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in Genome Biology
Verified
Journal Article
Open access
PDF file
WLWei-Cheng Liang
Wei-Cheng Liang
CWCheuk-Wa Wong
Cheuk-Wa Wong
PLPu-Ping Liang
Pu-Ping Liang
MSMai Shi
Mai Shi
YCYe Cao
Ye Cao
JZJin-fang Zhang
Jin-fang Zhang
Circular RNAs are a class of regulatory RNA transcripts, which are ubiquitously expressed in eukaryotes. In the current study, we evaluate the function of a novel circRNA derived from the β-catenin gene locus, circβ-catenin. Circβ-catenin is predominantly localized in the cytoplasm and displays resistance to RNase-R treatment. We find that circβ-catenin is highly expressed in liver cancer tissues when compared to adjacent normal tissues. Silencing of circβ-catenin significantly suppresses malignant phenotypes in vitro and in vivo, and knockdown of this circRNA reduces the protein level of β-catenin without affecting its mRNA level. We show that circβ-catenin affects a wide spectrum of Wnt pathway-related genes, and furthermore, circβ-catenin produces a novel 370-amino acid β-catenin isoform that uses the start codon as the linear β-catenin mRNA transcript and translation is terminated at a new stop codon created by circularization. We find that this novel isoform can stabilize full-length β-catenin by antagonizing GSK3β-induced β-catenin phosphorylation and degradation, leading to activation of the Wnt pathway. Our findings illustrate a non-canonical function of circRNA in modulating liver cancer cell growth through the Wnt pathway, which can provide novel mechanistic insights into the underlying mechanisms of hepatocellular carcinoma.

13 May 2023 in Phytomedicine
Verified
Journal Article
Closed access
RWRui-Jia Wen
Rui-Jia Wen
XDXin Dong
Xin Dong
HZHao-Wen Zhuang
Hao-Wen Zhuang
FPFeng-Xiang Pang
Feng-Xiang Pang
SDShou-Chang Ding
Shou-Chang Ding
JZJin-fang Zhang
Jin-fang Zhang

1 June 2018 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
LFLu Feng
Lu Feng
LSLiu Shi
Liu Shi
YLYing-Fei Lu
Ying-Fei Lu
BWBin Wang
Bin Wang
TTTao Tang
Tao Tang
JZJin-fang Zhang
Jin-fang Zhang
Long noncoding RNAs (lncRNAs), which serve as important and powerful regulators of various biological activities, have gained widespread attention in recent years. Emerging evidence has shown that some lncRNAs play important regulatory roles in osteoblast differentiation of mesenchymal stem cells (MSCs), suggesting a potential therapeutic strategy for bone fracture. As a recently identified lncRNA, linc-ROR was reported to mediate the reprogramming ability of differentiated cells into induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs) self-renewal. However, other functions of linc-ROR remain elusive. In this study, linc-ROR was found to be upregulated during osteogenesis of human bone-marrow-derived MSCs. Ectopic expression of linc-ROR significantly accelerated, whereas knockdown of linc-ROR suppressed, osteoblast differentiation. Using bioinformatic prediction and luciferase reporter assays, we demonstrated that linc-ROR functioned as a microRNA (miRNA) sponge for miR-138 and miR-145, both of which were negative regulators of osteogenesis. Further investigations revealed that linc-ROR antagonized the functions of these two miRNAs and led to the de-repression of their shared target ZEB2, which eventually activated Wnt/β-catenin pathway and hence potentiated osteogenesis. Taken together, linc-ROR modulated osteoblast differentiation by acting as a competing endogenous RNA (ceRNA), which may shed light on the functional characterization of lncRNAs in coordinating osteogenesis.

10 November 2020 in Cancer Communications
Verified
Journal Article
Open access
PDF file
ZTZhenye Tang
Zhenye Tang
ZXZhenhua Xu
Zhenhua Xu
XZXiao Zhu
Xiao Zhu
JZJin-fang Zhang
Jin-fang Zhang
Cancer cells are abnormal cells that can reproduce and regenerate rapidly. They are characterized by unlimited proliferation, transformation and migration, and can destroy normal cells. To meet the needs for cell proliferation and migration, tumor cells acquire molecular materials and energy through unusual metabolic pathways as their metabolism is more vigorous than that of normal cells. Multiple carcinogenic signaling pathways eventually converge to regulate three major metabolic pathways in tumor cells, including glucose, lipid, and amino acid metabolism. The distinct metabolic signatures of cancer cells reflect that metabolic changes are indispensable for the genesis and development of tumor cells. In this review, we report the unique metabolic alterations in tumor cells which occur through various signaling axes, and present various modalities available for cancer diagnosis and clinical therapy. We further provide suggestions for the development of anti‐tumor therapeutic drugs.

4 December 2024 in Drug Resistance Updates
Verified
Journal Article
Open access
CSChuan-Jian Shi
Chuan-Jian Shi
FPFeng-Xiang Pang
Feng-Xiang Pang
YLYu-He Lei
Yu-He Lei
LDLi-Qiang Deng
Li-Qiang Deng
FPFu-Zhen Pan
Fu-Zhen Pan
JZJin-fang Zhang
Jin-fang Zhang
Emerging evidence demonstrates that long non-coding RNAs (lncRNAs) play a crucial role in sorafenib resistance in hepatocellular carcinoma (HCC), and lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a dysregulated lncRNA in sorafenib-resistant HCC cells. However, the underlying regulatory mechanisms of MALAT1 in sorafenib-resistant HCC cells remain unclear. In the present study, we demonstrated that 5-methylcytosine (m5C) methylation catalyzed by NSUN2 and ALYREF contributed to the RNA stability and upregulation of MALAT1. The NSUN2/ALYREF/MALAT1 signaling axis was activated in sorafenib-resistant cells, and the upregulation of MALAT1 inhibited sorafenib-induced ferroptosis to drive sorafenib resistance. Mechanistically, MALAT1 maintained the mRNA stability of SLC7A11 by directly binding to ELAVL1 and stimulating its cytoplasmic translocation. Furthermore, we explored a new synergetic strategy for the treatment of HCC by combining MALAT1 inhibitor MALAT1-IN1 with sorafenib. The results demonstrated that MALAT1-IN1 significantly enhanced sorafenib efficacy for the treatment of HCC both in vitro and in vivo. Collectively, our work brings new insights into the epigenetic mechanisms of sorafenib resistance and offers an alternative therapeutic strategy targeting ferroptosis for sorafenib-resistant HCC patients.

19 June 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MLMin‐Yi Lv
Min‐Yi Lv
CSChuan‐Jian Shi
Chuan‐Jian Shi
FPFei‐Fei Pan
Fei‐Fei Pan
JSJiang Shao
Jiang Shao
LFLu Feng
Lu Feng
WFWei-ming Fu
Wei-ming Fu